Search results
Added:
3 weeks ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
6 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses…
View more
Added:
1 year ago
Added:
7 months ago
Discover the sex-specific challenges in aortic stenosis diagnosis and management with Prof Nicole Karam (European Hospital Georges Pompidou, Paris, FR).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, explores the critical pathophysiological differences between men and women that impact diagnostic approaches and therapeutic decision-making…
View more
Added:
2 years ago
In this video series, first presented at the ESC Congress 2023 held in Amsterdam, Prof Roxana Mehran, Dr Antoinette Neylon, Dr Martin Swaans, Prof Raphael Rosenhek and Prof Haim Danenberg discuss the Expand II TAVR pivotal trial design and the rational for investigating the treatment of moderate aortic stenosis patients with Evolut™ TAVI, provide practical Echo imaging recommendations to improve…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
An exploratory analysis of the EARLY TAVR trial has found that the benefits of early transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS) are consistent, regardless of baseline left ventricular (LV) health.¹ This suggests that waiting for LV deterioration may not be the optimal strategy for timing intervention.MethodologyThis analysis used data from the EARLY…
View more
Added:
11 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Added:
3 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Added:
11 months ago
Added:
6 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights…
View more